1249-C THE EFFECT OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE ON LIVER FIBROSIS PROGRESSION AND REGRESSION IN VIRUS-RELATED LIVER DISEASE: A MULTICENTER LONGITUDINAL STUDY Felice Cinque 1 , Jovana Milic 2 , Stefano Renzetti 3 , Federico Motta 2 , Jenny Bischoff 4 , Dana Kablawi 5 , Wesal Elgretli 6 , Giulia Besutti 2,7 , Giuseppe Mancini 2,7 , Sara Esperti 2,7 , Marianna Menozzi 2,7 , Stefano Calza 3 , Cristina Mussini 2,7 , Valentina Menozzi 2,7 , Maria Daria Di Trapani 2,7 , Juergen Rockstroh 4 , Giovanni Guaraldi 2,7 and Giada Sebastiani 1,8 , (1)Mcgill University Health Centre, Montreal, Canada, (2)University of Modena and Reggio Emilia, Modena, Italy, (3)University of Brescia, Brescia, Italy, (4)University Hospital Bonn, Bonn, Germany, (5)Mcgill University Health Centre, (6)Mcgill University, Montreal, Canada, (7)Policlinico of Modena, Modena, Italy, (8)Mcgill University Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a definition of fatty liver not requiring the exclusion of secondary causes of liver diseases, such as HIV and viral hepatitis

Remember, your journey to better health is unique, and we're here to support you with expert care and comprehensive wellness services every step of the way.
Therefore, this study aimed to develop a simple and sensitive bioanalytical method using liquid chromatographytandem mass spectrometry (LCMS/MS) and determine the pharmacokinetics and brain distribution of liraglutide in rats
Whether you are just starting or looking to optimize your current path, we provide the tools and expertise to help you move forward with confidence